Showing 4861-4870 of 8483 results for "".
- Laser for Oncychomycosis Clearedhttps://practicaldermatology.com/news/20120202-laser_for_oncychomycosis_cleared/2459872/Recently FDA-cleared for the temporary increase of clear nail in patients with onychomycosis, Sciton's ClearSense handpiece provides optimum laser delivery for JOULE treatment to safely provide effective treatment for ski
- From EADV: Povorcitinib Maintains Efficacy Through 24 Weeks in STOP-HS Programhttps://practicaldermatology.com/news/from-eadv-povorcitinib-maintains-efficacy-through-24-weeks-in-hs-phase-3-data/2483429/New 24-week results from the phase 3 STOP-HS trial program suggest that investigational oral JAK1 inhibitor povorcitinib provided sustained clinical benefits in adults with moderate to severe hidradenitis suppurativa (HS), according to findings presented at the 2025
- Low Recurrence Observed in MIS Cases With Clear Biopsy Marginshttps://practicaldermatology.com/news/low-recurrence-observed-in-mis-cases-with-clear-biopsy-margins/2483319/A new retrospective cohort study suggests that diagnostic excisional biopsy alone maya be efficacious for select cases of melanoma in situ (MIS) that are neither lentigo maligna (LM) nor acral lentiginous melanoma (ALM) subtypes.
- IL-17 Inhibitors Not Linked to MACE: Analysishttps://practicaldermatology.com/news/il-17-inhibitors-not-linked-to-maces/2483300/Results from a large French case–time–control study revealed no association between the administration of interleukin (IL)-17 receptor A inhibitors and major adverse cardiovascular events (MACE). Researchers used data from mo
- Biologics Most Likely to Be Continued After MACE: Studyhttps://practicaldermatology.com/news/biologics-most-likely-to-be-continued-after-mace-study/2483287/Biologic therapies were linked with greater treatment persistence than non-biologic systemic agents or phototherapy among patients with psoriasis who experience major adverse cardiovascular events (MACE), according to findings from a retrospective study of Korean n
- Study: Tralokinumab Demonstrates Durable Response, High Retention in AD Patientshttps://practicaldermatology.com/news/tralokinumab-shows-strong-one-year-results-in-real-world-ad-study/2483171/The long-term use of tralokinumab in adults with moderate-to-severe atopic dermatitis (AD). Over a 52-week period, the IL-13 inhibitor demonstrated clinically meaningful and sustained improvements across multiple outcome measures, with a favorable safety profile and
- Analysis: Global Prevalence of Hidradenitis Suppurativa Higher Than Previously Estimatedhttps://practicaldermatology.com/news/analysis-global-prevalence-of-hidradenitis-suppurativa-higher-than-previously-estimated/2483148/The estimate of the global prevalence of hidradenitis suppurativa (HS) sits at 0.99%, which notably higher than prior global figures, according to a new analysis. The research team compiled data from 25 population-based studies
- JAK Inhibitors Linked to Lower Adjunctive Therapy Use Than Dupilumab in ADhttps://practicaldermatology.com/news/jak-inhibitors-linked-to-lower-adjunctive-therapy-use-than-dupilumab-in-ad/2483122/Patients with atopic dermatitis (AD) treated with oral Janus kinase (JAK) inhibitors used fewer adjunctive therapies over the long term compared to those receiving dupilumab, according to a retrospective study published ahead of print in
- Review: Psoriasis May Increase Infection Risk After Hip Arthroplastyhttps://practicaldermatology.com/news/review-psoriasis-may-increase-infection-risk-after-hip-arthroplasty/2483053/Patients with psoriasis undergoing total hip arthroplasty (THA) may face a higher risk of postoperative infection, with evidence regarding total knee arthroplasty (TKA) outcomes remaining inconclusive, according to a new systematic review,
- HS Patients on Adalimumab Face Higher Risk of Serious Infections than PsO Counterpartshttps://practicaldermatology.com/news/hs-patients-on-adalimumab-face-higher-risk-of-serious-infections-than-pso-counterparts/2483028/Patients with hidradenitis suppurativa (HS) initiating adalimumab face a significantly higher risk of serious, noncutaneous infections requiring hospitalization compared with patients with psoriasis, a new cohort study finds.